<DOC>
	<DOCNO>NCT01962805</DOCNO>
	<brief_summary>This study double-blind crossover study female healthy volunteer compare pharmacokinetics safety either 1 6 day dose two different formulation Proellex vaginal administration . Each formulation designate either Treatment A Treatment B . A total 8 subject meet eligibility criterion randomize receive either Treatment A Treatment B first assign treatment . Subjects receive single dose Treatment A daily dose Treatment B 6 day . After 7-day washout period subject receive alternative treatment . On day treatment Treatment A first last day treatment Treatment B subject remain clinic overnight undergo 32-hour pharmacokinetic assessment follow time point : 0 , 0.5 , 1 , 2 , 4 , 8 , 12 , 16 , 20 , 24 , 28 32 hour administration study drug . For Treatment B study drug administer clinic day trough blood sample drawn .</brief_summary>
	<brief_title>Comparison Two Formulations Proellex Vaginal Administration</brief_title>
	<detailed_description />
	<criteria>Speak , read , understand English Spanish willing able provide write informed consent institutional review board ( IRB ) approve form prior initiation study procedure ; Healthy , premenopausal female age 1847 ; History menstrual event occur regular cycle Agreement attempt become pregnant Agrees use condom method birth control ( hormonal method , contraceptive sponge , spermicide cervical cap ) course study ; Has negative pregnancy test Screening visit . An exception pregnancy test requirement grant subject report surgical sterilization medical history Normal laboratory value clinically insignificant finding screen determined Investigator ; Subject willing remain clinic overnight PK assessment Days 0 , 6 8 Day 14 . Subject postmenopausal woman , define either ; six ( 6 ) month ( immediately prior screen visit ) without menstrual period , prior hysterectomy and/or oophorectomy Subject pregnant lactating attempt expect become pregnant study Women abnormally high liver enzymes liver disease . Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) exceed 1.5 x upper limit normal ( ULN ) AND total bilirubin exceed 1.5 x ULN screening confirm repeat ) . Received investigational drug 30 day prior screen study Women history polycystic ovary syndrome ( PCOS ) Concurrent use testosterone , progestin , androgen , estrogen , anabolic steroid , dehydroepiandrosterone ( DHEA ) hormonal product least 2 week prior screen study . Use oral contraceptive precede 2 week . Use DepoProveraÂ® precede 6 month . Has intrauterine device ( IUD ) place Women currently use narcotic Women currently take spironolactone Infectious disease screen positive HIV Hepatitis A , B C. Clinically significant abnormal finding screen examination condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>